Drugs / DOTAP:Chol-TUSC2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01455389 | Feb 2014 → Oct 2016 | lung cancer | Genprex, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DOTAP:Chol-TUSC2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01455389 ↗ |
| Known as | FUS1 | “DOTAP:Chol-TUSC2 (previously FUS1) is a drug that helps transfer a gene called TUSC2 into cancer cells.” NCT01455389 ↗ |
| Route | Intravenous | “DOTAP:Chol-TUSC2 is given by vein as an infusion over 25-35 minutes” NCT01455389 ↗ |